Suchergebnisse - (Subject:"Siltuximab")

PubPharm (226)

141

Current diagnosis and treatment of Castleman's disease

enthalten in: Revista clinica espanola | 2016

von González García, A. | Moreno Cobo, M. | Patier de la Peña, J.

142

Monoclonal antibodies - A new era in the treatment of multiple myeloma

enthalten in: Blood reviews | 2016

von Jelinek, T. | Hajek, R.

143

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma : an open-label phase I trial

enthalten in: Blood cancer journal | 2016

von Shah, J. | Feng, L. | Thomas, S. | +8

144

Update and new approaches in the treatment of Castleman disease

enthalten in: Journal of blood medicine | 2016

von Chan, K. | Lade, S. | Prince, H. | +1

145

Siltuximab : a targeted therapy for idiopathic multicentric Castleman disease

enthalten in: Immunotherapy | 2016

von Fajgenbaum, D. | Kurzrock, R.

146

Update and new approaches in the treatment of Castleman disease

in: Journal of Blood Medicine | 2016

von Chan KL | Lade S | Prince HM | +1

147

Emerging treatments in Castleman disease – a critical appraisal of siltuximab

in: Biologics: Targets & Therapy | 2016

von Koff JL | Lonial S

148

Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-a-positive breast cancer

in: Breast Cancer: Targets and Therapy | 2016

von Casneuf T | Axel AE | King P | +6

149

Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies : A new era begins

enthalten in: Leukemia & lymphoma | 2016

von Magarotto, V. | Salvini, M. | Bonello, F. | +2

150

Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer

enthalten in: Breast cancer (Dove Medical Press) | 2016

von Casneuf, T. | Axel, A. | King, P. | +6